{
    "clinical_study": {
        "@rank": "137728", 
        "arm_group": {
            "arm_group_label": "FACTOR X", 
            "arm_group_type": "Experimental", 
            "description": "At the Baseline Visit, eligible children will receive a bolus dose of 50 IU/kg FACTOR X.  After the Baseline Visit, children will be treated with FACTOR X prophylactically for a period of 12 months (52 weeks).\nA dosing regimen of 40-50 IU/kg twice a week is recommended, but is not mandatory.  Each dose of FACTOR X must not exceed 60 IU/kg."
        }, 
        "brief_summary": {
            "textblock": "The primary objective of the study is to assess the efficacy of FACTOR X in the prevention\n      of bleeding when given as routine prophylaxis over 12 months.\n\n      The secondary objectives of the study are:\n\n        1. To assess the pharmacokinetics of FACTOR X after a single dose of 50 IU/kg.\n\n        2. To assess the safety of FACTOR X when given as routine prophylaxis over 12 months."
        }, 
        "brief_title": "A Study to Investigate BPL's Factor X in the Prophylaxis of Bleeding in Children <12 Years", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Factor X Deficiency", 
        "condition_browse": {
            "mesh_term": [
                "Factor X Deficiency", 
                "Hemorrhage"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Children with hereditary severe FX deficiency (FX:C <1 IU/dL, based on their lowest\n             reliable FX:C recorded).\n\n          2. Children under 12 years old, whose parent/guardian has given written informed\n             consent.\n\n          3. Assent of child (for children aged 6-11 years).\n\n          4. Children with a history of severe bleeding (a minimum of one bleed with a bleed score\n             of 3 or 4, Appendix XI) or a mutation in the F10 gene causing a documented severe\n             bleeding phenotype.\n\n        Exclusion Criteria:\n\n        The presence of any one of these criteria makes the child ineligible:\n\n          1. Children with a history of inhibitor development to FX or a positive result at the\n             Screening Visit (quantitative result of >0.6 BU).\n\n          2. Children who have thrombocytopenia (platelets <50 x 109/L).\n\n          3. Children who have clinically significant renal disease (serum creatinine >200\n             umol/L).\n\n          4. Children who have clinically significant liver disease (serum ALT levels greater than\n             three times the upper normal limit).\n\n          5. Children known to have other coagulopathy or thrombophilia.\n\n          6. Children who have known or suspected hypersensitivity to the investigational\n             medicinal product or its excipients.\n\n          7. Children with a history of unreliability or non-cooperation.\n\n          8. Children who are participating or have taken part in another trial within the last 30\n             days.\n\n          9. Children who are planning more than 4 weeks' continuous absence from the locality of\n             the investigational site, between the Screening Visit and the 12 Month Visit.\n\n             ."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "11 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01721681", 
            "org_study_id": "Ten 02", 
            "secondary_id": "2012-003093-98"
        }, 
        "intervention": {
            "arm_group_label": "FACTOR X", 
            "intervention_name": "FACTOR X", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "November 13, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom", 
                    "zip": "WC1N 3JH"
                }, 
                "name": "Great Ormond Street Hospital"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase III Open, Multicentre Study to Investigate the Safety, Pharmacokinetics and Efficacy of BPL's High Purity Factor X in the Prophylaxis of Bleeding in Factor X Deficient Children Under the Age of 12 Years", 
        "other_outcome": {
            "description": "Adverse events, haematology, serum biochemistry, PT and APTT, viral serology, FX inhibitor screens, vital signs, physical examination, infusion site observations, genotype analysis (optional) and number of exposure days.\nArchive samples will be collected before first dose of FACTOR X and at the End-of-Study Visit.", 
            "measure": "Safety Outcomes", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 28 days days after the final dose of FACTOR X."
        }, 
        "overall_contact": {
            "email": "miranda.norton@bpl.co.uk", 
            "last_name": "Miranda Norton, Dr", 
            "phone": "+44 (0)208 957 2661"
        }, 
        "overall_contact_backup": {
            "email": "kate.gillanders@bpl.co.uk", 
            "last_name": "Kate Gillanders", 
            "phone": "+44 (0)208 957 2562"
        }, 
        "overall_official": {
            "affiliation": "Great Ormond Street Hospital", 
            "last_name": "Ri Liesner, Dr", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The efficacy criteria will be 'excellent', 'good', 'poor' or 'unassessable' and will be based on the number of major and minor breakthrough bleeds, and the number of excessive bleeding episodes following injury.", 
            "measure": "The primary efficacy variable is the investigator's assessment of the efficacy of FACTOR X in the prevention of bleeding when given as routine prophylaxis over 12 months", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01721681"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "For children equal to or greater than 1 year old.", 
                "measure": "Area Under Curve (AUC)", 
                "safety_issue": "Yes", 
                "time_frame": "predose, 30 mins, 4 hours, 24 hours, 48 hours and 72 hours"
            }, 
            {
                "description": "For children < 1 year old for for children equal to or > 1 year old whose bodyweight is less than 10.5kg", 
                "measure": "Area Under Curve (AUC)", 
                "safety_issue": "Yes", 
                "time_frame": "At two post-dose timepoints : 4 hours and 72 hours, or 30 mins and 48 hours, or 4 hours and 24 hours or 30 mins and 72 hours"
            }
        ], 
        "source": "Bio Products Laboratory", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bio Products Laboratory", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}